Compare NBTB & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBTB | HCM |
|---|---|---|
| Founded | 1856 | 2000 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.6B |
| IPO Year | N/A | N/A |
| Metric | NBTB | HCM |
|---|---|---|
| Price | $41.88 | $14.15 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 3 | 1 |
| Target Price | ★ $52.33 | $13.75 |
| AVG Volume (30 Days) | ★ 208.6K | 28.1K |
| Earning Date | 10-27-2025 | 08-07-2025 |
| Dividend Yield | ★ 3.53% | N/A |
| EPS Growth | ★ 5.89 | N/A |
| EPS | ★ 3.02 | 0.53 |
| Revenue | ★ $629,728,000.00 | $602,197,000.00 |
| Revenue This Year | $27.08 | N/A |
| Revenue Next Year | $9.17 | $15.54 |
| P/E Ratio | $13.89 | ★ $5.26 |
| Revenue Growth | ★ 16.88 | N/A |
| 52 Week Low | $37.31 | $11.51 |
| 52 Week High | $52.44 | $19.50 |
| Indicator | NBTB | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 55.23 | 37.36 |
| Support Level | $40.80 | $14.11 |
| Resistance Level | $42.58 | $14.63 |
| Average True Range (ATR) | 0.97 | 0.26 |
| MACD | 0.12 | -0.00 |
| Stochastic Oscillator | 71.45 | 26.31 |
NBT Bancorp Inc is a financial holding company that operates through its subsidiaries. The company's principal sources of revenue include management fees and dividends it receives through its subsidiaries. Its business, predominantly conducted through NBT Bank, consists of providing commercial banking, retail banking, and wealth management services to customers in its market area, which includes upstate New York, northeastern Pennsylvania, southern New Hampshire, western Massachusetts, Vermont, southern Maine, and central and northwestern Connecticut. The company's reportable segments are Banking and Retirement Plan Administration. A majority of its revenue is generated from the Banking segment.
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.